IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#2219
Positioning
Market Dominance
Services
Healthcare
$7.8B
Helmy Eltoukhy
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, LDT, CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible. Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients.
Headcount
1.8K
HQ Base
Pending Verification
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = GH ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$YALA Yalla Group Ltd | 75 | 89 | 99 | 80 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$GRVY GRAVITY Co., Ltd. | 75 | 82 | 96 | 71 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ISSC INNOVATIVE SOLUTIONS & SUPPORT INC | 73 | 81 | 88 | 94 | 25.0x | 14.1x | 17.1% | 10.3% | 35.5% | 14.6% | 10.1% | 105.2% | 0.0% | 41.0x | $244M | VS | |
$AER AerCap Holdings N.V. | 72 | 60 | 87 | 84 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$HCSG HEALTHCARE SERVICES GROUP INC | 72 | 74 | 88 | 88 | 7.1x | 6.1x | 28.9% | 20.8% | 20.8% | 9.9% | 9.3% | 8.5% | 0.0% | 1.0x | $1.2B | VS | |
$LQDT LIQUIDITY SERVICES INC | 72 | 90 | 88 | 68 | 24.9x | 14.3x | 14.1% | 8.3% | 45.7% | 8.5% | 6.2% | 28.1% | 0.0% | 0.0x | $736M | VS | |
$TRTNpA Triton International Ltd | 71 | 70 | 89 | 70 | - | 1.7x | 0.0% | - | 97.4% | 58.0% | 37.4% | - | 8.8% | 264.0x | $2.5B | VS | |
$EDU New Oriental Education & Technology Group Inc. | 71 | 83 | 52 | 77 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$NTES NetEase, Inc. | 71 | 88 | 93 | 68 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$UTI UNIVERSAL TECHNICAL INSTITUTE INC | 70 | 86 | 86 | 72 | 43.2x | 16.0x | 15.3% | 5.8% | 100.0% | 6.9% | 5.2% | 15.1% | 0.0% | 24.0x | $1.8B | VS | |
$GH Guardant Health, Inc. | 49 | 30 | 30 | 88 | - | - | 125.1% | -19.6% | 64.3% | -49.8% | -45.3% | 49.6% | 0.0% | - | $7.8B | ||
| SECTOR BENCH | - | - | - | - | - | 23.7x | 11.7x | 5.7% | 2.4% | 64.6% | 4.5% | 2.8% | 8.6% | 0.0% | 0.3x | - | REF |
Guardant Health, Inc. (GH) receives a "Reduce" rating with a composite score of 48.7/100. It ranks #2219 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Outperforming peers — winners tend to keep winning over 3-12 months
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Services sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for GH.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 30 | 17 | +13ALPHA |
| MOMENTUM | 88 | 95 | -7DRAG |
| VALUATION | 30 | 23 | +7ALPHA |
| INVESTMENT | 31 | 37 | -6DRAG |
| STABILITY | 57 | 62 | -5NEUTRAL |
| SHORT INT | 42 | 36 | +6ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROIC -37.4% vs WACC 8.8% (spread -46.2%)
GM 64% vs sector 65%, OM -50% vs sector 5%
Capital turnover 1.06x, R&D intensity 37.1%
Rev growth 50%, 8yr history
Interest coverage -463.7x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Guardant Health, Inc. (GH) as a Reduce with a composite score of 48.7/100 at a current price of $95.40. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential.
Guardant Health, Inc. holds a top-quartile position (#0 of 50) within the Services sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 48.7/100 places it at rank #2219 in our full universe.
The near-term outlook is constructive, with revenue growing at 50% and momentum in the 88th percentile confirming positive market sentiment. The combination of strong top-line growth and favorable price dynamics suggests the company is executing well on its growth strategy.
No Moat
Medium
Poor
Fair Value
Gross margins of 64% signal strong pricing power.
Returns on equity of 125.1% exceed cost of capital.
Positive momentum indicates institutional accumulation.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
Guardant Health, Inc. represents a reduce based on multi-factor quantitative performance.
Guardant Health, Inc. receives a Reduce rating from our analysis, with a composite score of 48.7/100 and 2 out of 5 stars, ranking #2219 out of 7,333 stocks. GH's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
GH's quality score of 30/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of 125.1% (sector avg: 5.7%), gross margins of 64.3% (sector avg: 64.6%), net margins of -45.3% (sector avg: 2.8%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 30/100, GH appears somewhat expensive relative to its fundamentals. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
Guardant Health, Inc.'s investment score of 31/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 49.6% vs. a sector average of 8.6% and a return on assets of -19.6% (sector: 2.4%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
GH shows strong momentum characteristics with a score of 88/100. The stock has been trending above key moving averages, indicating solid demand from institutional buyers. Revenue growth stands at 49.6% year-over-year, while a beta of 1.00 reflects its sensitivity to broader market moves. This level of momentum typically signals sustained investor confidence and favorable near-term price action.
With a stability score of 57/100, GH exhibits average financial resilience. Key stability metrics include a beta of 1.00. While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
The short interest score of 42/100 for GH suggests somewhat elevated bearish positioning by institutional traders. With a $7.8B market cap (mid-cap), Guardant Health, Inc. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
Guardant Health, Inc. is a mid-cap company in the Services sector, ranked #0 of 50 in its sector (100th percentile) and #2219 of 7,333 overall (70th percentile). Key comparisons include ROE of 125.1% exceeding the 5.7% sector median and operating margins of -49.8% below the 4.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Services peers.
While GH currently exhibits a REDUCE profile, superior opportunities exist within the SERVICES sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Services Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Quality (30) would have the largest impact on the composite score.
ROE 2079% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin IN LINE WITH SECTOR BENCHMARKS
Op. Margin 1206% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
Eventide Asset Management sold 114,922 shares of Mirum Pharmaceuticals in Q3, but the position's value increased by approximately $50.70 million to $184.92 million due to the stock's 89% surge over the past year. The share reduction appears to be portfolio management rather than a loss of confidence, as Mirum posted strong Q3 revenue growth of 47% and raised full-year guidance, with the company now representing the fund's second-largest equity holding.
This acquisition comes as analysts remain intrigued by the company’s long-term growth prospects.
Operator: Thank you for attending the Guardant Health Q4 2025 Earnings Call. My name is Cameron, and I
Guardant Health Inc (GH) reports a 39% revenue increase in Q4 2025, driven by oncology advancements and strategic expansions, despite ongoing cash flow challenges.
Guardant Health (GH) Q4 2025 earnings call: Shield adoption surge, oncology growth, 2026 revenue guidance, margins and cash flow path—read key takeaways.